

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

February 10, 2015

Bombay stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Kind Attn.: Mr. Kapoor
Mr. Goopalkrishnan

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra – (East)
Mumbai – 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjara Pole,
Ahmedabad – 380 015


Dear Sir

Re.: Press Release

We are forwarding you herewith copy of press release proposed to be published in the newspapers in the matter of unaudited financial results for the quarter and nine month ended on December 31, 2014, the same may please receive in order.

Thanking you

Yours faithfully
For **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus Cadila Net Profit up by 52% in Q3

Ahmedabad, February 10, 2015

For the third quarter ended 31st December 2014, Cadila Healthcare Limited registered a Net Profit of Rs. 282 crores, up by 52% from Rs. 186 crores in the corresponding period last year. The company registered a Total Income from Operations of Rs. 2190 crores up by 17% from Rs. 1872 crores in the corresponding period last year, on a consolidated basis.

During the quarter, the company's business in the US registered a growth of 42% and Emerging Markets business grew by 23%. During the quarter, the company filed 5 additional ANDAs with the US FDA taking the cumulative ANDA filings to 255.

During the quarter, the company launched Exemptia, the world's first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis. Exemptia is given as a 40 mg subcutaneous injection once every alternate week. The therapy is currently marketed by Zydus Biovation - a new division launched to exclusively market this ground breaking therapy.

The group's R&D pipeline which comprises 25 biologics (incl. novel biologics), is being developed to treat auto immune disorders like arthritis, cancer, infertility and stroke.
